HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avon and Gillette post first quarter double-digit sales gains.

This article was originally published in The Rose Sheet

Executive Summary

AVON MEXICO FIRST QUARTER PRETAX PROFITS REDUCED BY ABOUT $10 MIL. primarily due to the devaluation of the Mexican peso, the company announced April 20. However, Avon Chairman and CEO James Preston noted, "we think the worst is behind us in Mexico and the currency impact should lessen in succeeding quarters because of revised marketing and sales plans being implemented there." At a March 30 analysts' meeting in New York City, Avon predicted "a significant gain in market share in most of the categories in which we compete" in Mexico in 1995 ("The Rose Sheet" April 3, p. 10)

You may also be interested in...



Polish Industry Fighting Against Advertising Tax On Supplements

Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.

England’s NICE Future Proofs Approach To Using Data

UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.

Krka Responds To Romanian Allegations

Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.

UsernamePublicRestriction

Register

RS001531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel